[go: up one dir, main page]

BRPI0416680A - inibidores da forma mutante de kit - Google Patents

inibidores da forma mutante de kit

Info

Publication number
BRPI0416680A
BRPI0416680A BRPI0416680-9A BRPI0416680A BRPI0416680A BR PI0416680 A BRPI0416680 A BR PI0416680A BR PI0416680 A BRPI0416680 A BR PI0416680A BR PI0416680 A BRPI0416680 A BR PI0416680A
Authority
BR
Brazil
Prior art keywords
mutant form
kit
mutant
form inhibitors
inhibitors
Prior art date
Application number
BRPI0416680-9A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416680A publication Critical patent/BRPI0416680A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"INIBIDORES DA FORMA MUTANTE DE KIT". A presente invenção refere-se ao tratamento de doenças dependentes de KIT que são caracterizadas por uma forma mutante de KIT pelo qual o KIT mutante é identificado e um inibidor apropriado do KIT mutante selecionado a partir de midostaurina, vatalanib e composto A é administrado.
BRPI0416680-9A 2003-11-18 2004-11-17 inibidores da forma mutante de kit BRPI0416680A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
BRPI0416680A true BRPI0416680A (pt) 2007-02-13

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416680-9A BRPI0416680A (pt) 2003-11-18 2004-11-17 inibidores da forma mutante de kit

Country Status (28)

Country Link
US (3) US8017621B2 (pt)
EP (2) EP1686997B1 (pt)
JP (3) JP4762150B2 (pt)
KR (1) KR101153647B1 (pt)
CN (3) CN1882344A (pt)
AT (1) ATE428426T1 (pt)
AU (1) AU2004290902B2 (pt)
BR (1) BRPI0416680A (pt)
CA (1) CA2546189C (pt)
CY (1) CY1110354T1 (pt)
DE (1) DE602004020654D1 (pt)
DK (1) DK1686997T3 (pt)
ES (1) ES2324917T3 (pt)
HK (1) HK1093680A1 (pt)
HR (1) HRP20090390T1 (pt)
IL (2) IL175578A (pt)
MA (1) MA28176A1 (pt)
MX (1) MXPA06005598A (pt)
NO (1) NO20062694L (pt)
NZ (1) NZ547195A (pt)
PL (1) PL1686997T3 (pt)
PT (1) PT1686997E (pt)
RU (2) RU2362562C2 (pt)
SG (1) SG139747A1 (pt)
SI (1) SI1686997T1 (pt)
TN (1) TNSN06138A1 (pt)
WO (1) WO2005049032A1 (pt)
ZA (1) ZA200603905B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
CN101010082A (zh) * 2004-08-31 2007-08-01 诺瓦提斯公司 米哚妥林用于治疗胃肠道基质瘤的用途
EP1879584B1 (en) * 2005-05-02 2016-06-22 Novartis AG Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
CN103638028A (zh) 2005-05-02 2014-03-19 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CN101267837B (zh) * 2005-07-20 2010-12-15 彼得·瓦伦特 用于治疗系统性肥大细胞增生症的组合物
PT1959957E (pt) * 2005-12-06 2012-10-29 Novartis Ag Derivados de pirimidilaminobenzamida para o tratamento de neurofibromatose
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
PT2237783E (pt) * 2008-01-23 2014-12-23 Novartis Ag Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib
WO2015082887A2 (en) * 2013-12-02 2015-06-11 Bergenbio As Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
AU7821398A (en) 1997-06-06 1998-12-21 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CN1282253A (zh) 1997-11-13 2001-01-31 海斯塔泰克有限责任公司 小肽和用于治疗哮喘和炎症的方法
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
EP1483401A1 (en) 2002-03-13 2004-12-08 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
EP1667719B1 (en) * 2003-09-19 2010-11-24 Novartis AG Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
CN103638028A (zh) 2005-05-02 2014-03-19 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
PL1686997T3 (pl) 2009-09-30
ZA200603905B (en) 2008-11-26
CN101693031A (zh) 2010-04-14
RU2006121447A (ru) 2008-01-10
IL229124A0 (en) 2013-12-31
ATE428426T1 (de) 2009-05-15
JP2011121973A (ja) 2011-06-23
CA2546189A1 (en) 2005-06-02
RU2009110449A (ru) 2010-09-27
NZ547195A (en) 2010-06-25
US20120157441A1 (en) 2012-06-21
PT1686997E (pt) 2009-07-17
MA28176A1 (fr) 2006-09-01
JP2013241438A (ja) 2013-12-05
AU2004290902B2 (en) 2008-09-25
DK1686997T3 (da) 2009-07-27
RU2362562C2 (ru) 2009-07-27
JP2007511567A (ja) 2007-05-10
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
EP1686997A1 (en) 2006-08-09
NO20062694L (no) 2006-06-12
IL175578A0 (en) 2008-04-13
MXPA06005598A (es) 2006-08-11
CN1882344A (zh) 2006-12-20
CN102274230B (zh) 2015-07-01
SI1686997T1 (sl) 2009-08-31
HRP20090390T1 (hr) 2009-08-31
EP1917965A1 (en) 2008-05-07
EP1686997B1 (en) 2009-04-15
US8017621B2 (en) 2011-09-13
KR101153647B1 (ko) 2012-06-18
DE602004020654D1 (de) 2009-05-28
TNSN06138A1 (fr) 2007-11-15
US20100179179A1 (en) 2010-07-15
AU2004290902A1 (en) 2005-06-02
US20070213317A1 (en) 2007-09-13
CA2546189C (en) 2013-04-23
WO2005049032A1 (en) 2005-06-02
RU2405553C1 (ru) 2010-12-10
CN102274230A (zh) 2011-12-14
HK1093680A1 (en) 2007-03-09
US8124611B2 (en) 2012-02-28
KR20060101761A (ko) 2006-09-26
JP4762150B2 (ja) 2011-08-31
SG139747A1 (en) 2008-02-29
IL175578A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
NO20062694L (no) Inhibitor av mutant form av KIT
ECSP045429A (es) Combinacion de compuestos organicos
NO20034056D0 (no) Proliferative sykdommer
ATE414697T1 (de) Nf-kb-inhibitoren
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
NO20044459L (no) Anvendelse av IL-18-inhibitorer for behandlingen og/eller forebyggingen av perifere vaskulaere sykdomrner
DE60118953D1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
EA200700909A1 (ru) Азаиндолкарбоксамиды
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
ECSP055844A (es) Nuevos compuestos triciclicos
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
WO2003086309A3 (en) NF-κB INHIBITORS
NO20053247D0 (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
ATE433983T1 (de) Thiadibenzoazulenderivate zur behandlung von entzündlichen erkrankungen
EP1511474A4 (en) PROCESSING PROCESS
HN2003000228A (es) Derivados benzufurano y benzotiofeno utiles en el tratamiento de desordenes hiper - proliferativos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL